Abstract: Transdermal pharmaceutical preparations for the treatment of Parkinson's disease containing a combination of at least two active substances selected from the following groups of active substances: dopamine agonists and L-dopa, monoamine oxidase inhibitors, anticholinergics, NMDA-receptor antagonists, sympathomimetics; at least two of the said active substances being members of different active substance groups.

Abstract: The invention relates to a dermal or transdermal therapeutic system comprising a cover foil with barrier effect against gas, odour and volatile light substances. Said invention is characterised in that the cover foil is provided with at least one substrate and with at least one layer consisting of an inorganic-organic hybrid polymer (Ormocer).

Abstract: The invention relates to a transdermal therapeutic system (TTS) releasing an active pramipexol agent during a time ranging from 4 to 7 hours.

Abstract: (S)-N-ethyl-N-methyl-3-[1-(dimethylamino)ethyl]-phenyl carbamate (formula (1)) or at least one active ingredient according to formula (2) for the preventive protection of people from poisoning caused by cholinesterase inhibitors.

Abstract: A process for dispensing pressure-sensitive adhesive laminates (3) or laminate sections from a movable primary (1) onto a movable secondary carrier band (2), the laminates (3), upon deflection of the primary band (1) around a dispenser edge (4), being detached and dispensed onto the secondary band (2), is characterized in that the primary band (1) is provided with at least one separation line or predetermined breaking line, thus subdividing it into at least two strips (5, 5?), and that the strips are individually drawn from separate sections (4?, 4?) of the dispenser edge (4).

Abstract: The invention relates to transdermal therapeutic systems containing at least one steroid hormone and propylene glycol monocaprylate as permeation enhancers. The invention also relates to methods for the production of said systems and to the use of the same in hormone substitution therapy and contraception.

Abstract: The invention relates to a transdermal therapeutic system (TTS) consisting of a rear layer, a protective layer and an active-substance-containing polymer layer. The polymer matrix comprises a polyacrylate which contains an extremely reduced number of functional groups. In one particular embodiment, the polyacrylate is free from hydroxyl groups and/or carboxyl groups.

Abstract: A transdermal therapeutic system for administering sex hormones which is provided with an active substance-impermeable backing layer, a pressure-sensitive adhesive polymer matrix connected therewith and containing a sex hormone as well as skin penetration-enhancing substances, and with a protective layer detachable prior to application, is characterized in that said polymer matrix contains the sex hormone testosterone as well as a mixture of at least one penetration-enhancing substance from the group comprising fatty alcohol esters and fatty acid esters, and at least one readily volatile penetration-enhancing substance.

Abstract: Transdermal therapeutic systems (TTS) whose structure comprises a polymer matrix containing active substances, and a backing layer, and which contain at least one light-sensitive active substance are characterized in that the said TTS contain at least one colourless substance which absorbs light in the UV region, does not have any inherent pharmacological action, is dispersed or dissolved in the polymer matrix of the TTS, and/or is homogeneously distributed in the backing layer of the TTS.

Abstract: An apparatus provides for increasing storage stability of substrate portion which is provided with a self-adhesive layer covered by a carrier layer and which and are packed in bags. The adhesive layer is protected by the carrier layer which projects beyond the self-adhesive layer, at least in some areas The adhesive layer is protected from adhesive bonding with packaging material of the bag in that in projecting regions, on a side of the carrier layer assigned to the substrate portion, there are arranged elevations, fixed to the side-or shaped out from it, as spacers with respect to the bag, and, in addition to the elevations on that side of the carrier layer which is assigned to the substrate portion, elevations designed as spacers are arranged on an opposite side of the carrier layer.

Abstract: A transdermal or transmucosal pharmaceutical administration form for treating nicotine dependency or for disaccustoming smokers, comprising nicotine, a nicotine salt, a nicotine derivative or a nicotinergic substance in combination with at least one further active substance is characterized in that as additional active substance(s) it comprises at least one substance which acts on the central nervous system.